Purchase Order HHSD2002016M90017P
Award Date
5/31/16
Potential Completion Date
5/31/20
Potential Value
$113K
Federal Agency
CDC Pittsburgh
Awardee
Bioreliance Corporation
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Atlanta, GA 30329, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $248,779.00 firm-fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Bioreliance Corporation, a foreign-owned for-profit organization. The contract is for follow-up in vivo oncogenicity testing on the Expi293F Master Cell Bank to support the CDC's influenza vaccine development efforts. The testing must be compliant with 21 CFR and current Good Laboratory Practices (cGLP) and is expected to be completed within 24 weeks. This contract was not set...
This is a delivery order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Bioreliance Corporation, a foreign-owned for-profit organization. The $83,273.28 firm fixed-price contract is for Option Year 1 of Contract HHSN261200900022I, which covers master cell bank testing, specifically sterility testing under Package 1, Line Item 32. Bioreliance Corporation, through its Life Sciences Services division, provides endotoxin,...
This federal contract was awarded to Bioreliance Corporation, a foreign-owned, for-profit organization, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The contract, valued at $6,065,128.00, is a definitive contract with a cost-plus-fixed-fee pricing type. Bioreliance, through its Life Sciences Services Division, will provide a range of specialized testing services to support investigational new drug...
The Centers for Disease Control and Prevention (CDC) awarded a $249,662 purchase order to Cell Microsystems Inc. to procure cell lines in support of the agency's biomedical research and public health initiatives. The firm fixed price contract has a period of performance from September 11, 2023 through October 30, 2023 for delivery of the requested cell lines to CDC facilities in Durham, North Carolina. No subcontractors or set aside designations were identified. This award advances the CDC's...
This federal contract award, valued at $32,797.00, was issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Bioreliance Corporation, a foreign-owned, for-profit organization that provides specialized testing services. The contract is for vector biosafety testing, including sterility testing of vector supernatant samples. Bioreliance has a history of supporting various government health initiatives, including providing services to...
This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Bioreliance Corporation, a foreign-owned, for-profit organization, for $89,113.67. The contract is for LINE ITEM 3: CELL CULTURE IDENTIFICATION (380801.BSV) services. Bioreliance Corporation, through its Life Sciences Services Division, provides specialized testing services to support investigational new drug applications,...
This is a firm fixed-price delivery order contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Bioreliance Corporation, a foreign-owned, for-profit organization. The contract, valued at $127,772.70, is for biosafety testing of a 293T master cell bank used for production of patient-specific lentiviral vectors encoding. This contract does not have a set-aside designation, indicating Bioreliance's competitive standing in the...
The Department of Health and Human Services Centers for Disease Control and Prevention in Pittsburgh awarded a purchase order to Bioreliance Corporation's Life Sciences Services Division for $237,266.00 to provide laboratory services, including sterility testing. This firm fixed price contract has a completion date of September 18, 2023. Bioreliance, a foreign-owned for-profit organization, will provide sterility testing using direct inoculation methods, Limulus Amebocyte Lysate (LAL) testing...
This is a Firm Fixed Price Delivery Order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Bioreliance Corporation, a foreign-owned for-profit organization. The contract, valued at $87,849.55, is for sterility testing services (STERILITY (510120GMP.BSV)) with a completion date of November 20, 2014. Bioreliance, through its Life Sciences Services Division, is a specialized provider of microbiological examination,...
This is a federal contract award to Bioreliance Corporation, a foreign-owned, for-profit organization, by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract, which does not have a set-aside designation, is for $33,780.61 and involves the delivery of sterility testing services under Line Item 57 of Package 2. Bioreliance has been a long-standing provider of specialized testing services to various government...